Skip to content

Intervention study of autoimmune bullous disease with imatinib

Intervention study of autoimmune bullous disease with imatinib - Treatment of autoimmune bullous disease with imatinib

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030865
Enrollment
10
Registered
2018-01-17
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune bullous disease

Interventions

After diagnosis of pemphigus group or pemphigoid group, oral administration of prednisolone is started according to the following: #1. In case of the initial onset: 0.5 mg/kg/day #2. In case of recu

Sponsors

Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: #1 Diagnosed as pemphigus group or pemphigus group. #2 Those not planning treatment with steroid pulse therapy or IVIG therapy. #3 The age at the time of consent acquisition is over 20 years old. #4 The latest blood test and liver function test within 4 weeks before registration satisfy all of the following. Number of neutrophils >= 1,500 / mm3 Platelet count >= 75,000 / mm3 AST (GOT) <120 IU / L ALT (GPT) <120 IU / L Total bilirubin <1.8 mg / dL 5) In the case of men, those agreeing to contrace up to 4 weeks after the start of the study drug administration from the date of final administration of the test drug. In the case of women, one after surgical contraceptive surgery such as postmenopausal (more than 1 year since the last menstruation), or bilateral oophorectomy. 6) With regard to participation in this study, written informed consent has been obtained from the patient himself.

Exclusion criteria

Exclusion criteria: 1) There is a history that has allergy to Imatinib. 2) It has one of the following complications. Serious heart disease or its past liver disorder, renal disorder 3) Consent Acknowledging participation in other exams within 4 weeks before acquisition. 4) In addition, patients judged unsuitable for the trial responsible doctor or shared medical doctor to safely carry out this study.

Design outcomes

Primary

MeasureTime frame
Improvement of severity of autoimmune bullous disease

Secondary

MeasureTime frame
Changes in autoantibody titer in blood Changes in antibody titer in body fluid (saliva, content of blisters)

Countries

Japan

Contacts

Public ContactTakashi Nomura

Kyoto University Hospital Department of Dermatology

tnomura_@_kuhp.kyoto-u.ac.jp075-751-3310

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026